A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed

Inclusion criteria

• Healthy subjects aged 2months (60-89 days) and 3months (90-119 days) ；
• Willing to provide proof of identity
• Subjects aged 2 months have not been vaccinated with DTaP, IPV, Hib, or 13-valent pneumococcal polysaccharide conjugate vaccine;
• Subjects of 3 months have not been inoculated with DTaP vaccine, and IPV (only group A3）；
• Subjects'guardians or trustees are able to understand and sign the informed consent voluntarily, comply with the requirements of the clinical study plan.

Exclusion criteria

• With temperature >37.0°C on axillary setting before vacciation;
• With a medical history of diphtheria, pertussis or tetanus;
• Had contact with individuals with confirmed pertussis, diphtheria and tetanus diseases in their families in the past 30 days;
• Premature birth (delivery before the 37th week of pregnancy)or low birth weight (birth weight< <2500g);
• History of dystocia, suffocation rescue, neurological damage;
• With congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
• History of epilepsy, convulsions or convulsions, or have a family history of mental illness;
• History of abnormal blood coagulation (such as coagulation factor deficiency, coagulopathy);
• Had received immune enhancement or inhibitor therapy (continuous oral or instillation for more than 14 days);
• History of severe allergic reactions to vaccination, such as difficulty breathing, urticaria;
• Any prior administration of blood products in last 3 month;
• Any prior administration of attenuated live vaccine in last 14 days;
• Any prior administration of subunit or inactivated vaccines in last 7 days;
• Plans to participate in or is participating in any other drug clinical study;
• Has any other factors judged by investigators that make them unfit to participate in the clinical trial